Business

DarioHealth, Clover Health and eHealth also released third-quarter financial results.  

HATCo will spend a total of $550 million in capital funding to invest in technologies and innovation.

Adam Hutchinson, oVRcome founder and CEO, discusses reducing phobias using VR exposure therapy, how the company fills the gap in VR psychiatric care access for providers and patients, and its trial on combatting social anxiety with VR.

The company also reported Q3 2024 earnings, noting total revenue of $76.4 million, adjusted EBITDA of $7.3 million and a net loss of $14.7 million.

The acquisition includes all of NeuroReality's assets, including its flagship rehabilitation product, Koji's Quest.

The company will use the funds to expand in Asian and U.S. markets, advance its AI algorithms and grow its workforce.

Attorney Everett Wilson, managing partner at Polsinelli's Miami office, discusses overall changes in Medicare and Medicare Advantage - and how the recent benefits changes affect consumers, payers and plans.

The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.

The acquisition includes Jack's Canadian clinical assets, the authority to operate 16 medical clinics across 13 Canadian cities and the rights to operate clinics in Walmart stores in Canada.  

The company offers a marketplace for individuals seeking addiction and mental health treatment. It will use the funds to scale its workforce and expand its reach.